antibodies
| 3 min read
Researchers showed that an oral medication can activate worn-out T cells.
| 1 min read
The expanded partnership reflects strong demand for Lonza’s global biologics outsourcing platform, spanning diversified clinical and commercial manufacturing programs.
| 4 min read
Biogen’s $850 million move to secure full global rights to felzartamab highlights a deeper shift in how antibody-driven diseases are being understood and treated.
Available on Demand
Learn how to detect aggregation early and quantify proteins, peptides, and ADCs fast with combined UV/Vis and DLS in one low-volume, automated workflow.
| 10 min read
Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.
| 4 min read
Sepsis antibody breakthroughs, a billion-dollar KRAS deal, and FDA’s push to rebuild domestic drug manufacturing led the drug discovery news this week.
| 9 min read
With new insight into IgE biology, a new, two-pronged strategy for eliminating the pathogenic immune cells that lead to allergies emerges.
| 4 min read
A new method to tag and track different antibody drugs in the same mouse reduces the number of animals needed in preclinical studies.
| 4 min read
Scientists probed how tick proteins influenced host immunity, paving the way for mRNA vaccines to block Lyme and other tick-borne diseases.
| 3 min read
Omalizumab could be a better treatment for children with food allergies compared to oral immunotherapy, mainly due to fewer side effects.
